BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Masoumi E, Tahaghoghi-Hajghorbani S, Jafarzadeh L, Sanaei MJ, Pourbagheri-Sigaroodi A, Bashash D. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. J Control Release 2021;340:168-87. [PMID: 34743998 DOI: 10.1016/j.jconrel.2021.10.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Domvri K, Petanidis S, Zarogoulidis P, Anestakis D, Charalampidis C, Tsavlis D, Huang H, Freitag L, Hohenforst-Schmidt W, Matthaios D, Katopodi T, Porpodis K. Engineered Hybrid Treg-Targeted Nanosomes Restrain Lung Immunosuppression by Inducing Intratumoral CD8+T Cell Immunity. Int J Nanomedicine 2022;17:4449-68. [PMID: 36172007 DOI: 10.2147/IJN.S346341] [Reference Citation Analysis]
2 Zhang L, Zhang Y, Bao J, Gao W, Wang D, Pan H, Elmouki I. Cuproptosis Combined with lncRNAs Predicts the Prognosis and Immune Microenvironment of Breast Cancer. Computational and Mathematical Methods in Medicine 2022;2022:1-32. [DOI: 10.1155/2022/5422698] [Reference Citation Analysis]
3 Zhu J, Cai C, Li J, Xiao J, Duan X. CD47-SIRPα axis in cancer therapy: Precise delivery of CD47-targeted therapeutics and design of anti-phagocytic drug delivery systems. Medicine in Drug Discovery 2022;15:100139. [DOI: 10.1016/j.medidd.2022.100139] [Reference Citation Analysis]
4 Ang L, Li J, Dong H, Wang C, Huang J, Li M, Zhao M, Su C, Wu Q. Chimeric Oncolytic Adenovirus Armed Chemokine Rantes for Treatment of Breast Cancer. Bioengineering (Basel) 2022;9:342. [PMID: 35892755 DOI: 10.3390/bioengineering9080342] [Reference Citation Analysis]
5 Chen C, Wang R, Chen X, Hou Y, Jiang J. Targeting CD47 as a Novel Immunotherapy for Breast Cancer. Front Oncol 2022;12:924740. [DOI: 10.3389/fonc.2022.924740] [Reference Citation Analysis]
6 Pan X, Gao A, Lin Z. Fluorescence imaging of tumor immune contexture in immune checkpoint blockade therapy. International Immunopharmacology 2022;106:108617. [DOI: 10.1016/j.intimp.2022.108617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sanaei M, Razi S, Pourbagheri-sigaroodi A, Bashash D. The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles. Translational Oncology 2022;18:101364. [DOI: 10.1016/j.tranon.2022.101364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Mohseninia A, Dehghani P, Bargahi A, Rad-Malekshahi M, Rahimikian R, Movahed A, Reza Farzaneh M, Mohammadi M. Harnessing self-assembling peptide nanofibers toprime robust tumor-specific CD8 T cell responses in mice. Int Immunopharmacol 2022;104:108522. [PMID: 35032825 DOI: 10.1016/j.intimp.2022.108522] [Reference Citation Analysis]